Results released by Novavax on Monday, June 14 reveal another promising vaccine candidate for the world’s battle against COVID-19. UNC joined the Novavax phase III clinical trial at the end of 2020, with Cindy Gay, MD, associate professor in the Division of Infectious Diseases, as the principal investigator.
“It is critical to continue our research on COVID-19 vaccines because we aren’t at the finish line yet. We need multiple options in order to be able to provide vaccines to people in the U.S. and across the globe in a timely manner,” Gay, a member of the UNC Institute for Global Health and Infectious Diseases, said when the trial began.
Read more from the UNC Health and UNC School of Medicine Newsroom.